What is Leinco Technologies?
Founded in 1992, Leinco Technologies operates as a specialized manufacturer and service provider within the biotechnology industry. The company maintains a robust portfolio of early discovery research products, including monoclonal antibodies, recombinant proteins, and ELISA kits. Beyond its product catalog, Leinco serves as a premier partner for custom R&D and manufacturing, facilitating the transition from early-stage discovery to the development of protein therapeutics. Its market position is defined by its dual-role as both a supplier of essential life science reagents and a contract service provider for diagnostic and therapeutic innovators.
How much funding has Leinco Technologies raised?
Leinco Technologies has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Leinco Technologies
PPP
Public-Private Partnership
What's next for Leinco Technologies?
With the recent influx of capital, Leinco Technologies is well-positioned to scale its manufacturing capabilities and expand its footprint in the protein therapeutics market. The strategic focus will likely shift toward enhancing its custom R&D service offerings, which are increasingly vital for firms navigating the complexities of drug discovery. By leveraging this late-stage funding, the company aims to accelerate the development of next-generation reagents, thereby cementing its role as a foundational entity in the advancement of modern medical diagnostics and therapeutic breakthroughs.
See full Leinco Technologies company page
